Home Cart Sign in  
Chemical Structure| 866541-93-7 Chemical Structure| 866541-93-7

Structure of (R)-(-)-Gossypol acetic acid
CAS No.: 866541-93-7

Chemical Structure| 866541-93-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AT101 acetic acid, the R-(-) enantiomer of gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM.

Synonyms: AT-101 (acetic acid); AT-101 acetic acid; (R)-Gossypol acetic acid

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of (R)-(-)-Gossypol acetic acid

CAS No. :866541-93-7
Formula : C32H34O10
M.W : 578.61
SMILES Code : O=CC1=C(C(O)=C(C(C)C)C2=CC(C)=C(C3=C(C4=C(C(O)=C(C(C(C)C)=C4C=C3C)O)C=O)O)C(O)=C12)O.O=C(C)O
Synonyms :
AT-101 (acetic acid); AT-101 acetic acid; (R)-Gossypol acetic acid
MDL No. :MFCD00058385

Safety of (R)-(-)-Gossypol acetic acid

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H361
Precautionary Statements:P501-P202-P201-P280-P308+P313-P405

Isoform Comparison

Biological Activity

Target
  • Bcl-xL

    Bcl-xL, Ki:0.48 μM

  • Mcl-1

    Mcl-1, Ki:0.18 μM

  • Bcl-2

    Bcl-2, Ki:0.32 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
U937 leukemia cells 20 µM 12 hours AT-101 significantly increased apoptosis and mitochondrial injury in U937 leukemia cells, accompanied by caspase-3, caspase-9, and PARP cleavage, and cytochrome c release. Cell Death Dis. 2014 Jan 16;5(1):e998.
Jurkat T-lymphoblastic leukemia cells 20 µM 12 hours AT-101 significantly increased apoptosis in Jurkat T-lymphoblastic leukemia cells, accompanied by caspase-3, caspase-9, and PARP cleavage, and cytochrome c release. Cell Death Dis. 2014 Jan 16;5(1):e998.
HL-60 promyelocytic leukemia cells 20 µM 12 hours AT-101 significantly increased apoptosis in HL-60 promyelocytic leukemia cells, accompanied by caspase-3, caspase-9, and PARP cleavage, and cytochrome c release. Cell Death Dis. 2014 Jan 16;5(1):e998.
HUVECs 5 µM 18 hours AT-101 significantly enhanced the inhibitory effect of CDDP on the migration of HUVECs Drug Des Devel Ther. 2015 Jun 8;9:2887-910.
A2780 5 µM 24 hours GAA significantly reduced mitochondrial activity in A2780 cells, including basal OCR, ATP production, and Maximal OCR. J Transl Med. 2023 Jul 26;21(1):504.
SKOV3 5 µM 24 hours GAA significantly reduced mitochondrial activity in SKOV3 cells, including basal OCR, ATP production, and Maximal OCR. J Transl Med. 2023 Jul 26;21(1):504.
Primary human leukemia cells 20 µM 24 hours AT-101 significantly increased apoptosis in primary human leukemia cells, accompanied by caspase-3, caspase-9, and PARP cleavage, and cytochrome c release. Cell Death Dis. 2014 Jan 16;5(1):e998.
MM-B1 1.56–25 µM 24, 48, and 72 hours AT-101 significantly inhibited the survival of MM-B1 cells, with IC50 values of 9.30 μM at 48 hours and 5.59 μM at 72 hours. Front Pharmacol. 2018 Nov 6;9:1269.
H-Meso-1 1.56–25 µM 24, 48, and 72 hours AT-101 significantly inhibited the survival of H-Meso-1 cells, with IC50 values of 9.24 μM at 48 hours and 2.66 μM at 72 hours. Front Pharmacol. 2018 Nov 6;9:1269.
MM-F1 1.56–25 µM 24, 48, and 72 hours AT-101 significantly inhibited the survival of MM-F1 cells, with IC50 values of 9.32 μM at 48 hours and 5.10 μM at 72 hours. Front Pharmacol. 2018 Nov 6;9:1269.
U87MG 15 µM 48 hours To investigate the effects of AT-101 on protein expression in U87MG cells, results showed a significant downregulation of mitochondrial-related proteins. Autophagy. 2018;14(10):1693-1709.
U343 15 µM 48 hours To investigate the effects of AT-101 on protein expression in U343 cells, results showed a significant downregulation of mitochondrial-related proteins. Autophagy. 2018;14(10):1693-1709.
A549 cells 5 µM 48 hours AT-101 significantly enhanced the inhibitory effect of CDDP on the proliferation of A549 cells Drug Des Devel Ther. 2015 Jun 8;9:2887-910.
Human non-small cell lung cancer A549 cells 5 µM 6 hours To evaluate the effects of sequential treatment with AT-101 and cisplatin (CDDP) on the proliferation, migration, and apoptosis of A549 cells. The results showed that the sequential treatment significantly inhibited cell proliferation and migration and induced apoptosis. Drug Des Devel Ther. 2014 Dec 12;8:2517-29.
VCaP cells 1-10 µM 72 hours To evaluate the effect of AT-101 on VCaP cell viability, results showed that AT-101 dose-dependently decreased VCaP cell viability after 72 hours Neoplasia. 2007 Dec;9(12):1030-7.
PC-3 cells 1-10 µM 72 hours To evaluate the effect of AT-101 on PC-3 cell viability, results showed that AT-101 dose-dependently decreased PC-3 cell viability after 72 hours Neoplasia. 2007 Dec;9(12):1030-7.
PC-3 (prostate cancer cells) 8.72 ± 0.30 µM (IC50) 72 hours Evaluate the cytotoxicity of Gos/cRGD-LP on PC-3 cells, results showed that the IC50 of Gos/cRGD-LP was 9.53 ± 0.26 μM, significantly higher than that of free drug, indicating stronger cytotoxicity. Int J Nanomedicine. 2022 Jan 14;17:227-244.
HCT-116 (colon cancer cells) 6.32 ± 0.40 µM (IC50) 72 hours Evaluate the cytotoxicity of Gos/cRGD-LP on HCT-116 cells, results showed that the IC50 of Gos/cRGD-LP was 8.93 ± 0.41 μM, significantly higher than that of free drug, indicating stronger cytotoxicity. Int J Nanomedicine. 2022 Jan 14;17:227-244.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Mouse model intraperitoneally transplanted with #40a cells Intraperitoneal injection 0.1 mg Once a week, up to 17 weeks AT-101 significantly increased the median survival time of mice (7 weeks vs. 4.5 weeks) and reduced the risk of tumor development. Front Pharmacol. 2018 Nov 6;9:1269.
SCID mice VCaP prostate cancer xenograft model Oral 15 mg/kg 5 days per week, continuous treatment To evaluate the efficacy of AT-101 in combination with surgical castration in delaying the onset of androgen-independent prostate cancer growth, results showed that AT-101 combined with surgical castration significantly delayed the onset of androgen-independent prostate cancer growth Neoplasia. 2007 Dec;9(12):1030-7.
BALB/c Nude mice PC-3 tumor model Intravenous injection 15 mg/kg Once every three days, for 6 times in total Evaluate the antitumor effect of Gos/cRGD-LP in the PC-3 tumor model, results showed that Gos/cRGD-LP significantly inhibited tumor growth, with a tumor inhibition rate of over 74%. Int J Nanomedicine. 2022 Jan 14;17:227-244.
BALB/c Nude mice A2780 cell subcutaneous xenograft model Intraperitoneal injection 30 mg/kg Every other day for 3 weeks GAA significantly inhibited the growth of A2780 cell subcutaneous xenografts and did not cause weight loss or liver and kidney function impairment in mice. J Transl Med. 2023 Jul 26;21(1):504.
BALB/c Nude mice A549 xenograft model Oral gavage 35 mg/kg/day For 10 consecutive days To evaluate the effects of sequential treatment with AT-101 and cisplatin (CDDP) on tumor growth in the A549 xenograft model. The results showed that the sequential treatment significantly inhibited tumor growth and enhanced the expressions of Bcl-2 and Bcl-xL by downregulating the APE1/STAT3 signaling pathway. Drug Des Devel Ther. 2014 Dec 12;8:2517-29.
BALB/c Nude mice A549 xenograft model Oral and intraperitoneal injection 35 mg/kg/day 10 days Combination therapy of AT-101 and CDDP significantly inhibited tumor angiogenesis and tumor cell proliferation Drug Des Devel Ther. 2015 Jun 8;9:2887-910.
NOD/SCID mice U937 xenograft model Intraperitoneal injection 50 mg/kg Five times per week for 60 days AT-101 significantly inhibited tumor growth in the U937 xenograft mouse model, accompanied by RhoA/ROCK1/PTEN signaling activation and Akt inactivation. Cell Death Dis. 2014 Jan 16;5(1):e998.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.73mL

0.35mL

0.17mL

8.64mL

1.73mL

0.86mL

17.28mL

3.46mL

1.73mL

References

 

Historical Records

Categories